Pharmaceutical company Parnell Pharmaceuticals reported on Wednesday that it has developed the first antiviral Nomovid Nasal Spray in the US that is easy-to-use, low-cost and can be quickly made available over-the-counter for consumers for use against Sars-CoV-2.
The company added Nomovid is based upon a substance licensed from New Mexico Tech University to treat drug-resistant bacteria and fungi including MRSA and Candida auris.
However, the company is now filing with FDA for the COVID-19 indication as Nomovid Antiviral Nasal Spray showed very positive results against COVID-19. Since the nose is the main route of entry into the body of Sars-CoV-2, it has prepared it in a nasal spray, added its CEO.
In conjunction, the company has filed a White Paper to the US government programme Operation Warp Speed, seeking funding and an Emergency Use Authorization, which will allow the product to be manufactured and distributed during the Phase III Clinical Trials.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT